Rewinding heart cells could reduce scarring after a heart attack
When a heart attack kills part of the heart muscle, the human body has no way to replace it.
A new study from the Lifespan Research Institute shows that partial reprogramming of cardiomyocytes — the contractile muscle cells of the heart — can significantly reduce scar formation after a myocardial infarction. The researchers used so-called Yamanaka factors: four proteins capable of pushing cells back toward an embryonic state. Not fully, since complete reprogramming risks tumor formation, but partially. Just enough to restart cell division.
Adult heart muscle cells almost never divide. Shortly after birth, the heart loses that regenerative capacity almost entirely. What remains after a heart attack is scar tissue: functionally dead, mechanically stiff, and over time a driver of heart failure. The new approach breaks that deadlock. In mice given an artificial heart attack, partially reprogrammed cells were able to complete their cell division cycle. Something that normally stalls midway through.
Unsticking cells that get trapped in the cycle
The mechanism centers on a specific biological bottleneck: heart muscle cells attempting to divide get stuck in the G2/M phase of the cell cycle. They start dividing but never finish. Partial reprogramming appears to lift that block. The cells complete division, generating new functional heart tissue rather than scar. In the treated mice, the area of dead tissue after a simulated heart attack was measurably smaller than in controls.
Crucially, this is partial — not full — reprogramming. Complete cellular reset carries a real cancer risk, which for years was the central objection to using Yamanaka factors in living tissue. By carefully controlling the duration and intensity of exposure, the researchers avoided that outcome. In mice, at least.
The gap between a mouse heart and a human one
The mouse heart beats roughly ten times faster than the human heart, is far smaller, and differs in meaningful ways at the cellular level. Findings that hold in rodent cardiac tissue don’t automatically translate. The history of heart failure research is littered with promising mouse results that failed in human trials.
That said, the study fits into a rapidly growing field. Companies like Altos Labs and Turn Biotechnologies are pouring hundreds of millions of dollars into partial reprogramming as a broader anti-aging strategy. The scientific question of whether the approach works biologically is looking increasingly settled. What remains open is whether it can be made safe and precise enough for human hearts — and whether the heart is even the right place to start clinical translation.